Article
Outpatient Treatment of COVID-19 and the Development of Long COVID Over 10 Months: A Multi-Center, Quadruple-Blind, Parallel Group Randomized Phase 3 Trial
2023-03-06
Abstract excerpt
Background: Post-acute sequelae of COVID, termed “Long COVID”, is an emerging chronic illness potentially affecting ~10% of those with COVID-19. We sought to determine if outpatient treatment with metformin, ivermectin, or fluvoxamine could prevent Long COVID. <br><br>Methods: COVID-OUT (NCT04510194) was a decentralized, multi-site trial in the United States testing three medications (metformin, ivermectin, fluvox...
Topics
Open a Topic to create a Post that cites this publication.
Identifiers and source
- Literature Corpus work
- edc40a44-c76c-5170-b044-aa988501331b
- DOI
- 10.2139/ssrn.4375620
